You are on page 1of 3

EMMANUEL NORMANT, Pharm. D., Ph. D.

104 Sylvester Avenue


Winchester, MA 01890
781-721-1598
en1c03e9@westpost.net
DIRECTOR OF RESEARCH
Preclinical Studies / INDs / FDA
Cellular & Molecular Biology / HTS
Project Management / Technology Assessment
Automation / Publications / Presentations
Startups / GPCR / Team Building
A skilled cellular and molecular biology
researcher, I drove new drug discoveries for
industry-leading and startup pharmaceuticals,
including Pfizer and Infinity Pharmaceuticals.
I consistently collaborated with internal
teams, scientists, academics and vendors to
facilitate introduction of new candidates into
clinical trials and filing of INDs.
Adept at obtaining and applying cutting-edge
technology to enhance preclinical efforts, I
have expeditiously and cost-effectively
conducted research leading to superior
findings and results. I can contribute
immediately by:
* Utilizing advanced technology to develop
breakthrough drug candidates
* Establishing, training and leading effective
multi-functional teams
* Developing relationships and resources with
industry and academic professionals
* Working closely with marketing, legal and IP
departments to foster publication
* Explaining complex scientific theories to
professionals and lay people
While attending Paris University, I earned a
Masters in Biochemistry, a Pharm. D. and a
Ph.D. in Cellular and Molecular Biology. I
hold six patents and I have received awards
and grants from US and French institutions. I
have also authored numerous publications and
posters and presented at several international
conferences.
SELECTED ACCOMPLISHMENTS
Spurred IND filings by initiating and leading
collaboration. Seeking input from
collaborators was not a high-priority at
Infinity. Initiated fruitful interactions with
many professional and academic opinion
leaders. Built group to 50+ collaborators who
shared proprietary tools and published drug
activity data, facilitating new clinical
studies.
Spearheaded significant growth of drug-
discovery projects. Infinity pipeline of new
projects was not extensive. Enthusiastically
researched, created and formally presented
five new projects in front of entire company,
with three obtaining funding. Quickly gained
recognition as main initiator and provider of
new projects.
Introduced cutting edge technology to
facilitate new clinical trials. Pfizer needed
complex and costly machine to obtain real-time
ion-flux information. Sourced different
vendors and machines. Proposed and secured
$500K screening equipment. Ran four campaigns
leading to important drug discovery.
Keyed discovery of promising new drug
indication. Research of new indications for
clinical candidate was not optimal. Initiated
collaboration with Harvard Medical School
professor to combine Infinity drug with
another anti-cancer drug. Preliminary
experiments provided spectacular results,
leading to publication and possible clinical
trials.
Established strong publication/communication
culture. Infinity project team lacked driving
force to effectively communicate and publish
its findings. Infused get finished and publish
attitude. Fostered production of posters for
presentation at key meetings and publication
of reviews and scientific articles. Enhanced
company image.
Linked biology with automation to expedite HTS
assay. Infinity assay for high throughput
screening (HTS) campaign was time consuming.
Redeveloped and automated assay with fewer
steps. Accelerated campaign and brought hits
for further evaluation. Collaboration between
cell biologist and robotic engineer was key to
success.
CAREER HISTORY
Associate Director of Research, Preclinical
Studies, Infinity Pharmaceuticals, 2002-
Present. Lead 15-member multi-disciplinary
oncology research team responsible for new
indications and combinations, mechanisms of
action and resistance and Biomarkers for Phase
I and II drugs. Ran PD analysis (Phase 1 and
2). Filed INDs and IRBs for several
indications. Recruited as Senior Scientist in
2002 and promoted to Lead Senior Scientist in
2004.
Senior Scientist, Pfizer Inc. 1998-2002.
Managed target identification, assay
development and HTS efforts in Inflammation,
COPD, asthma and pain. Developed and ran
assays (SPA, FP, FRET). Implemented and led
Cell-based Assay Section (FLIPR, beta-
lactamase assay). Project Director for
screening program (GPCR).
Fellow, N.I.H., 1995-1998. Postdoctoral
fellowship at NICHD, section of Cellular
Neurobiology.

You might also like